Veröffentlichungsdatum: 18 Februar 2019
Projektträger – zwischengeschaltetes Finanzinstitut
The project will finance Alfasigma's R&D investments to be made in the period 2019-2022. In particular, financing will cover the promoter's research activities (clinical and regulatory development) for the development of innovative drugs in the areas of gastroenterology, vascular medicine and rheumatology.
By co-investing in this project, the EIB contributes to making medical treatments for what the healthcare system considers high priority diseases, whilst also fostering the generation of European scientific knowledge and acumen.
- Dienstleistungen - Erbringung von Freiberuflichen, Wissenschaftlichen und Technischen Dienstleistungen
Vorgeschlagene EIB-Finanzierung (voraussichtlicher Betrag)
EUR 100 million
Gesamtkosten (voraussichtlicher Betrag)
EUR 251 million
The project mainly concerns investments in R&D that are expected to be carried out in existing facilities already authorised for the same purpose and would therefore not require an environmental impact assessment (EIA) under the Directive 2011/92/EU. Full environmental details will be verified during the appraisal.
Alfasigma is a private company not operating in the utilities sector and not having the status of a contracting authority. Thus, it is not covered by EU Directives on procurement. However, the promoter's procurement procedures are expected to be in line with EIB guidelines for private sector projects. The Bank's services will verify details during the project due diligence.
Unterzeichnet - 13/09/2019
Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. The data provided on this page is therefore indicative and cannot be considered to represent official EIB policy (see also the Explanatory notes).